The information provided on this page is for reference only. Please refer to the latest information published by the partner company.
Hong Kong Cyclotron Laboratories Limited (HKCL) was established on January 23rd 2006 as a radio-pharmaceutical manufacturer specializing in PET drugs such as FDG. HKCL, together with its SUbsidiary, operates one of the largest PET radiopharmacy distribution network in Hong Kong with delivery service of PET drugs to hospitals, clinics, and imaging centers.
We are the first Hong Kong cyclotron and radio-pharmaceutical production laboratory that is built outside a hospital setting. We are also the first cyclotron facility in China region that employs a fully automated hand free robotic arm for PET drugs dispensing, further cutting down radiation exposure and human errors.
Positron Emission Tomography (PET) is a medical imaging technology useful in diagnosis, staging and monitoring of treatment effects in many diseases including cancers. Patients are injected with a PET radiopharmaceutical and scanned using a PET -CT scanner. The PET radiopharmaceuticals localize in different tissues/ organs of the body based on the biochemical changes due to difference diseases stage. A typical example is 18F-Fluorodeoxyglucose (18F-FDG), which is a radioactive glucose analogue. Since cancer cells consume large amount of glucose to support their fast metabolism, they can be imaged as intense spots with high uptake of 18F-FDG. As chemotherapy suppress tumor cells metabolism and growth, their 18F-FDG uptake will be lower after therapy. A such , clinicians are able to diagnose cancers and monitor treatment of cancers.